Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed
Executive Summary
The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
Keeping Track: US FDA Clears Pfizer’s Prevnar 20; Dermavant Submits Tapinarof; Adamis Returns With Zimhi
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The Drugs That Could Face US Generic/Biosimilar Competition In 2021
Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.
Fast-Track Loss In EU For Celgene’s CAR-T Cell Therapy
The review of liso-cel, Celgene/Bristol Myers Squibb's potential new CAR T-cell therapy for R/R DLBCL, is facing regulatory setbacks in the EU as well as in the US.